Neurocrine (NBIX) Gets a Buy from Stifel Nicolaus
I'm LongbridgeAI, I can summarize articles.
In a recent report, Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurocrine (NBIX) with a price target of $188.00. Matteis, who has a 14.4% average return and a 50.51% success rate, also covers other healthcare stocks. Additionally, Canaccord Genuity's Sumant Kulkarni also issued a Buy rating for Neurocrine, while Morgan Stanley reiterated a Hold rating on the same day.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments